NovaBridge Biosciences Cash Flow-to-Debt Ratio
NovaBridge Biosciences cash flow-to-debt ratio. NovaBridge Biosciences (NBP) has a Cash Flow-to-Debt Ratio of -0.54x as of June 2026, meaning its operating cash flow of $-16.40 Million could theoretically repay -1% of its total liabilities ($30.44 Million) in one year. Check cash flow quality index of NovaBridge Biosciences to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NovaBridge Biosciences (2017–2025)
Cash flow-to-debt ratio of NovaBridge Biosciences from 2017 to 2025. Historical debt coverage capacity for NovaBridge Biosciences across 9 annual periods. Check NovaBridge Biosciences cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NovaBridge Biosciences Cash Flow-to-Debt Ratio by Year (2017–2025)
NovaBridge Biosciences cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for NovaBridge Biosciences. For the full cash flow conversion analysis, see cash flow conversion of NovaBridge Biosciences.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.87x | $-20.60 Million | $4.23 Million | ▼ -6.6% |
| 2024 | -4.57x | $-384.29 Million | $84.08 Million | ▼ -692.6% |
| 2023 | -0.58x | $-72.85 Million | $126.34 Million | ▲ +44.3% |
| 2022 | -1.04x | $-1.10 Billion | $1.07 Billion | ▲ +82.6% |
| 2021 | -5.95x | $-973.09 Million | $163.42 Million | ▼ -1078.2% |
| 2020 | 0.61x | $433.56 Million | $712.19 Million | ▲ +364.6% |
| 2019 | -0.23x | $-867.98 Million | $3.77 Billion | ▼ -173.0% |
| 2018 | -0.08x | $-280.70 Million | $3.33 Billion | ▲ +55.7% |
| 2017 | -0.19x | $-252.16 Million | $1.33 Billion | — |